Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $174.10 -1.7%
EPS Growth %: -4.2%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
CCEL, MHGU, PLG, More
EPS Growth %: -4.2%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.65, $0.69 better than the analyst estimate of $0.96. Revenue for the quarter came in at $687.5 million versus the consensus estimate of $653.32 million.
GUIDANCE:
Neurocrine Biosciences sees FY2025 revenue of $2.5-2.55 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $200 at Truist Securities
- Jefferies Upgrades Friedrich Vorwerk Group SE (VH2:GR) to Hold
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
